AstraZeneca PLC became the latest pharma to strike a deal with Vanderbilt University Medical Center to discover and develop neurology drug candidates, inking a two-year research deal with the university on Jan. 14.
The British pharma said it had licensed rights to drugs addressing psychosis and other related symptoms of Alzheimer’s disease and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?